Related Experiment Videos
Overview of new immunosuppressive therapies
1University of Minnesota School of Medicine, Minneapolis, 55455, USA.
Current Opinion in Pediatrics
|April 14, 2000
Summary
This review examines recent immunosuppressive drugs, including cyclosporine A, tacrolimus, sirolimus, and mycophenolate mofetil, focusing on their use and risk-benefit profiles in pediatric patients. It highlights the evolving clinical experience with these vital medications.
Area of Science:
- Immunology
- Pediatric Pharmacology
- Drug Development
Background:
- The past five years have seen the emergence of novel immunosuppressive agents.
- Cyclosporine A, a mature drug, has a new formulation (Neoral).
- Tacrolimus, sirolimus, and mycophenolate mofetil are also key players in immunosuppression.
Purpose of the Study:
- To review new immunosuppressive drugs introduced in the last five years.
- To analyze the evolution of clinical experience with these agents.
- To address the risk-benefit considerations for pediatric use.
Main Methods:
- Literature review of immunosuppressive drugs.
- Focus on cyclosporine A (Neoral), tacrolimus, sirolimus, and mycophenolate mofetil.
- Analysis of pediatric application and risk-benefit data.
Main Results:
- Newer immunosuppressive drugs offer expanded therapeutic options.
- Clinical experience with tacrolimus, sirolimus, and mycophenolate mofetil is evolving.
- Cyclosporine A's new formulation (Neoral) is also discussed.
Conclusions:
- Pediatricians must carefully weigh the risks and benefits of these immunosuppressants.
- Continued research is needed to optimize the use of these drugs in children.
- The review provides insights into the latest advancements in immunosuppressive therapy for pediatric populations.